Oestrogen receptor-α variant mRNA expression in primary human breast tumours and matched lymph node metastases by Leygue, E et al.
Multiple oestrogen receptor-a (ER) mRNA species have been
identified in human breast cancer samples (Dowsett et al, 1997;
Murphy et al, 1997a, b). The significance of these variant tran-
scripts remains unclear. Although the ability to detect variant ER
proteins encoded by such variant transcripts remains controversial
(Park et al, 1996; Desai et al, 1997; Huang et al, 1997), alteration
of expression of some variant ER mRNAs has been found to occur
during both breast tumorigenesis (Leygue et al, 1996a,  b) and
breast cancer progression. With regard to the latter, we showed
previously that the expression of the truncated, clone 4 variant
(C4) ER mRNA (Dotzlaw et al, 1992) was significantly increased
relative to wild-type (WT) ER mRNA in a group of primary breast
tumours with multiple poor prognostic features compared with a
group of primary breast tumours with good prognostic features
(Murphy et al, 1995). The ‘poor’ prognostic features were defined
as the presence of lymph node metastases at the time of surgery,
large tumour size, lack of progesterone receptor (PR) expression
and high S-phase fraction, while ‘good’ prognostic features were
lack of nodal involvement, small tumour size, PR positivity and
low S-phase fraction. In the same study, the relative expression of
clone 4 ER variant mRNA was significantly higher in primary
breast tumours that were PR– than in those that were PR+
(Murphy et al, 1995). This suggested that altered ER variant
expression may be a marker of a more aggressive phenotype and
lack of endocrine sensitivity in human breast cancer. As a pre-
requisite to addressing such a possibility, we have investigated the
pattern of ER variant expression in a cohort of primary tumours
and their matched, concurrent lymph node metastases.
MATERIALS AND METHODS
Tumour selection and RNA isolation
Sections from 15 frozen primary human breast tumour samples
and their matched frozen lymph node metastases were provided by
the Manitoba Breast Tumour Bank (Winnipeg, MB, Canada). For
the primary tumour samples, the ER levels, determined by ligand-
binding assays, ranged from 0.8 fmol mg–1 protein to 89 fmol mg–1
protein with a median value of 17.5 fmol mg–1 protein. Thirteen
tumours were ER+ and two were ER– (ER+ was defined as
>3 fmol mg–1 protein). PR levels determined by ligand-binding
assays ranged from 2.9 fmol mg–1 protein to 112 fmol mg–1 protein
with a median value of 12.6 fmol mg–1 protein. Nine tumours were
PR+ and 6 were PR– (PR+ was defined as > 10 fmol mg–1 protein).
ER and PR values were available for only four of the lymph node
metastases and the ER and PR status as defined by ligand binding
did not differ from their matched primary tumour. RNA was
extracted from the sections using Trizol reagent (Gibco/BRL,
Ontario, Canada) according to the manufacturer’s instructions.
For validation of triple-primer polymerase chain reactions
(TP-PCR) by comparison with RNAase protection assays, a
second cohort of human breast tumour specimens (25 cases) was
also obtained from the Manitoba Breast Tumour Bank. Twenty of
these tumours were ER+, as determined by ligand-binding assay,
with values ranging from 4.5 to 311 fmol mg–1 protein (median
93 fmol mg–1). The five remaining cases were ER–, with values
ranging from 0 to 1.8 fmol mg–1 protein (median 0.9 fmol mg–1).
Total RNA was extracted from frozen tissues using guanidinium
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thiocyanate as previously described (Murphy and Dotzlaw, 1989).
The integrity of the RNA was confirmed by denaturing gel elec-
trophoresis as previously described (Murphy and Dotzlaw, 1989).
RNAase protection assay
Antisense riboprobes spanning the point at which the C4 ER
mRNA sequence diverges from the WT ER mRNA sequence
(Dotzlaw et al, 1992) were synthesized as previously described
(Dotzlaw et al, 1990). The level of C4 ER mRNA and WT ER
mRNA in 10 mg of total RNA was determined using an RNAase
Protection Assay kit (RPA II, Ambion, Austin, TX, USA)
following the manufacturer’s instructions. Briefly, RNA was
denatured at 80°C for 5 min in the presence of 5 ´ 105 d.p.m. 32P-
labelled riboprobe, then hybridized at 42°C for 16 h. Following
RNAase digestion, samples were electrophoresed on 6% acryl-
amide gels containing 7 M urea, dried and autoradiographed.
To quantify C4 and WT ER mRNAs within breast tumour
samples, a standard curve was established in each assay. C4 and WT
ER mRNAs (30, 125, 500 pg C4 RNA and 125, 500, 2000 pg WT
ER RNA) synthesized using T7 RNA polymerase were purified on a
Sephadex G-50 column and quantitated spectrophotometrically. WT
ER RNA was transcribed from linearized pHEO, which contains the
entire WT ER coding sequence but is missing the 3¢-untranslated
portion of the ER mRNA [(kindly provided by P Chambon,
Strasbourg, France (Green et al, 1986)]. Full-length C4 RNA was
transcribed from linearized pSK-C4 (Dotzlaw et al, 1992). Standard
RNAs were analysed together in the same assay as the breast tumour
mRNAs. Bands corresponding to the C4 ER mRNA and WT ER
mRNA protected fragments were excised from the gel and counted
after addition of 5 ml scintillant (ICN Pharmaceuticals, Inc., Irvine,
CA, USA) in a scintillation counter (Beckman Instruments, Inc.,
Fullerton, CA, USA). For each sample, absolute amounts of C4 and
WT ER mRNA were determined from the standard curve.
Reverse transcription, PCR and triple-primer (TP) PCR
For each sample, 1 mg of total RNA was reverse transcribed in a
final volume of 15 ml as described previously (Leygue et al,
1996a). One microlitre of the reaction mixture was taken for
subsequent amplification.
The primers and PCR conditions for the long-range PCR were
as previously described (Leygue et al, 1996c). The primers and
PCR conditions for measuring the relative expression of exon 5-
deleted and exon 7-deleted ER transcripts relative to WT ER tran-
scripts were as previously described (Leygue et al, 1996a).
The TP-PCR conditions were similar to those previously
described (Leygue et al, 1996b) with minor modifications. ERU
(5¢-TGTGCAATGACTATGCTTCA-3¢, sense, located in WT ER
exon 2; 792–811, as numbered in Green et al, 1986) and ERL (5¢-
GCTCTTCCTCCTGTTTTTAT-3¢, antisense, located in WT ER
exon 3; 940–921) primers allowed amplification of a 149-bp frag-
ment corresponding to WT ER mRNA. The C4-specific primer
(C4L, 5¢-TTTCAGTCTTCAGATACCCCAG-3¢, antisense; 1336–
1315, as numbered in Dotzlaw et al, 1992) spans the only region of
the C4 unique sequence that does not have any homology with
repetitive LINE-1 sequences (Dotzlaw et al, 1992). ERU and C4L
allowed amplification of a 536-bp fragment corresponding specif-
ically to C4 ER variant mRNA.
PCR amplifications were performed in a final volume of 10 ml in
the presence of 20 mMTris-HCl (pH 8.4), 50 mMpotassium chloride,
2m M magnesium chloride, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM
dGTP, 0.2 mM dCTP, 4 ng ml–1 of each primer (ERU, ERL and C4L),
0.2 units of Taq DNA polymerase (Gibco-BRL) and 1 mCi of [a-32P]
dCTP (3000 Ci mmol–1, ICN Pharmaceuticals, Irvine, CA, USA).




















Figure 1 (A) Autoradiogram of long-range RT-PCR (Leygue et al, 1996c)
results from two samples of primary breast tumours (P) and their matched
concurrent lymph node metastase (M). WT ER is the expected product
corresponding to the WT ER mRNA; D7 is the expected product
corresponding to the exon 7-deleted ER variant mRNA; D4 is the expected
product for the exon 4-deleted ER mRNA; D3-4 is the expected product for
the exon 3+4-deleted ER mRNA; D4/7 is the expected product for the exon
4+7-deleted ER mRNA. (B) Autoradiogram of RT-PCR results from two
samples of primary breast tumours (P) and their matched concurrent lymph
node metastase (M). D5 is the expected product corresponding to the exon
5-deleted ER variant mRNA. WT ER is the expected product corresponding
to the WT ER mRNA. (C) Autoradiogram of RT-PCR results from two
samples of primary breast tumours (P) and their matched concurrent lymph
node metastase (M). D7 is the expected product corresponding to the exon
7-deleted ER variant mRNA. WT ER is the expected product corresponding
to the WT ER mRNA. (D) Autoradiogram of TP-PCR results from two
samples of primary breast tumours (P) and their matched concurrent lymph
node metastase (M). C4 is the expected product corresponding to the clone 4
ER variant mRNA. WT ER is the expected product corresponding to the WT
ER mRNA. *Band coamplified with C4 and WT ER and shown to correspond
to an exon 2-duplicated ER variant mRNA980 E Leygue et al
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1 min at 72°C) using a thermocycler (Perkin Elmer). Four microlitres
of the reaction mix was then denatured by addition of 6 ml of 80%
formamide buffer and boiling before electrophoresis on 6% poly-
acrylamide gels containing 7 M urea (PAGE). Following electro-
phoresis, the gels were dried and exposed to Kodak XAR Film at
–70°C with two intensifying screens for 2 h.
Quantification of RT-PCR and TP-PCR
Bands corresponding to the variant ER mRNA and WT ER mRNA
were excised from the gel and counted after addition of 5 ml of
scintillant in a scintillation counter. The variant signal was
expressed as a percentage of the WT ER signal. It should be noted
that the percentage obtained reflects the relative ratio of the variant
to WT ER RT-PCR product and does not provide absolute initial
mRNA levels. Validation of this approach was described previ-
ously (Daffada et al, 1994, 1995; Leygue et al, 1996a, b). At least
two independent PCR assays were performed for each sample in
the comparison of RNAase protection assay with TP-PCR assays.
For assessment of matched primary and secondary breast tumour
samples, at least two and in most cases three independent PCR
reactions were performed and the mean determined.
The statistical significance of differences in the relative levels of
expression of any single ER mRNA variant between primary
tumour and lymph node metastasis was determined using the
Wilcoxon signed-rank test.
RESULTS
Determination of the pattern of exon-deleted ER variant
mRNA expression
Multiple ER variant mRNAs have been shown to be expressed in
any one breast tissue sample (Leygue et al, 1996a; Murphy et al,
1997a, b). To investigate the pattern of multiple exon-deleted ER
variant expression between primary breast tumours and their
matched lymph node metastases, a long-range RT-PCR approach
was used. This approach, based on the competitive amplification
of wild-type and exon-deleted ER variant cDNAs, using primers
annealing within exons 1 and 8, allows the evaluation of the rela-
tive pattern of expression of all exon-deleted ER variant transcripts
present in any individual sample (Leygue et al, 1996c; Fasco,
1997). Typical results are shown in Figure 1A. The pattern of
deleted ER mRNA expression between any one primary tumour
and its matched lymph node metastasis was conserved.
Determination of the relative expression of exon
5-deleted and exon 7-deleted ER variant mRNA
expression
Using a previously validated semiquantitative PCR approach
(Leygue et al, 1996a), the measurement of the relative expression
of specific individual exon-deleted ER variant mRNAs was also


















































Figure 2 (A) Quantitative comparison of the relative expression of exon 5-deleted variant ER mRNA in primary (P) human breast tumours and their concurrent
matched lymph node metastases (M). For each sample, the mean of three independent measures of exon 5-deleted ER relative expression expressed as a
percentage of the corresponding WT ER signal was determined as described in the Materials and methods section. (B) Quantitative comparison of the relative
expression of exon 7-deleted variant ER mRNA in primary (P) human breast tumours and their concurrent matched lymph node metastases (M). For each
sample, the mean of three independent measures of exon 7-deleted ER relative expression expressed as a percentage of the corresponding WT ER signal was
determined as described in the Materials and Methods section. (C) Quantitative comparison of the relative expression of clone 4 variant ER mRNA in primary
(P) human breast tumours and their concurrent matched lymph node metastases (M). For each sample, the mean of three independent measures of clone 4
relative expression expressed as a percentage of the corresponding WT ER signal was determined as described in the Materials and Methods sectionOestrogen receptor-a variants in metastases 981
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ER cDNA (Figure 1B) using primers in exons 4 and 6, and exon 7-
deleted ER cDNA (Figure 1C), using primers in exons 5 and 8,
were measured. The median value for the relative expression of the
exon 5-deleted ER for the primary tumours was 23.1% (range
17.3–94.3%) and the median value for the matched lymph node
metastases was 31.3% (range 14.9–200%). The scatter plot for
these results is shown in Figure 2A. The median relative expression
of the exon 7-deleted ER for primary tumours was 65% (range
39.3–184.9%) and the median value for the matched lymph node
metastases was 52.5% (range 35.5–126%). The scatterplot of these
results is shown in Figure 2B. There were no statistically signifi-
cant differences in the relative expression of either exon-deleted ER
mRNA between primary and concurrent metastatic tumours.
Comparison of RNAase protection assay and triple-
primer PCR assay for determination of the relative
expression of clone 4 truncated ER variant mRNA
expression
Another frequently expressed ER variant, which would not be
detected in the above assays, is the C4 ER mRNA. This variant
was previously found to be significantly elevated in a group of
primary breast tumours with poor prognostic features that included
concurrent lymph node metastases, compared with a group of
primary tumours with good prognostic variables that included lack
of concurrent nodal metastases (Murphy et al, 1995). Therefore, it
was relevant to determine the level of C4 ER variant expression in
primary breast tumours and their matched, concurrent lymph node
metastases.
In this previous study, we used RNAase protection assays to
measure WT and variant ER mRNA expression (Murphy et al, 1995).
However, in order to conduct this study using smaller tissue samples
(in particular from nodal metastases) and to ensure a close correlation
with the histological composition of the tissue, we used a previously
described TP-PCR assay (Leygue et al, 1996b) to measure the rela-
tive expression of C4 ER mRNA. To facilitate comparison of the
current data with our earlier study (Murphy et al, 1995), it was neces-
sary to compare the RNAase protection assay with the TP-PCR assay,
before proceeding to analyse the primary and secondary breast
tumour samples for C4 mRNA expression by TP-PCR.
RNA from 25 human breast tumours, selected to represent a
wide range of ER status by ligand-binding assay (Table 1), was
analysed in a standardized RNAase protection assay in order to
determine the absolute amount of C4 and WT ER mRNAs within
each sample. The signals corresponding to C4 and WT ER
mRNAs were quantified as described in Materials and Methods. In
each assay, known amounts of synthetic WT ER and C4 mRNAs
were analysed in parallel in order to establish a standard curve
allowing the determination of absolute levels of C4 and WT ER
mRNAs, expressed as pg 10 mg–1 RNA (Table 1). Because of the
very low C4 protected fragment signal (≤ 15 d.p.m.) in seven
tumours, it was not possible to determine confidently the absolute
amount of C4 mRNA in these samples (not detected, ND). All C4-
negative tumours by RNAase protection assay were from tumours
with ER values lower than 10 fmol mg–1 protein, as determined by
ligand-binding assay. The absolute amounts of C4 and WT ER
mRNAs in the remaining 18 tumours, as determined by RNAase
protection assay, varied from 2 to 83.9 pg 10 mg–1 RNA and from 9
to 3651 pg 10 mg–1 RNA respectively. For each sample, the C4
mRNA signal was expressed as a percentage of WT ER mRNA
signal (Table 1).
C4 ER mRNA relative expression was determined by TP-PCR
within the same 25 RNA samples as described in Materials and
Methods. Both C4 and WT ER cDNAs signals were detected in all
25 tumours studied, independent of their ER status as determined
by ligand-binding assay. C4 and WT ER signals were quantified as
described in Materials and Methods. The signal corresponding to
C4 was expressed as a percentage of the WT ER signal. Table 1
presents the average of a least two independent TP-PCR experi-
ments. Linear regression analysis (Figure 3) shows a highly signif-
icant correlation between C4 mRNA relative expression as




































r =0.932 P <0.0001
Figure 3 Linear regression analysis of clone 4 expression (expressed as a
percentage of the corresponding WT ER expression) as determined by TP-
PCR vs standardized RNAase protection assay in 18 human breast tumours
Table 1 C4 and WT ER mRNA expression in 25 human breast tumours, as
determined by RNAase protection assay and TP-PCR
Sample Ligand RNAase
no. binding protection TPPCR
ER C4 WT ER C4 C4
(fmol mg–1) (pg 10 mg–1) (pg 10 mg–1) (%) (%)
5 0.0 ND ND – 1.7
3 0.4 ND ND – 2.6
1 0.9 ND ND – 3.1
24 1.2 6.2 105.1 5.9 3.3
4 1.8 ND ND – 3.7
23 4.5 10.0 54.3 18.4 22.7
8 5.8 ND 26.8 – 2.8
7 6.3 ND 224.6 – 3.4
2 8.7 ND 9.0 – 2.2
19 10.0 22.6 902.9 2.5 3.6
10 17.8 5.3 146.4 3.6 4.1
13 25.0 2.3 112.0 2.0 1.0
15 44.0 5.0 148.5 3.4 5.9
22 57.0 11.8 153.6 7.7 14.1
11 90.0 2.5 129.1 1.9 1.7
21 96.0 9.6 263.4 3.6 2.2
14 105.0 4.6 94.4 4.9 5.0
17 111.0 26.7 320.3 8.3 9.1
9 121.0 4.6 277.7 1.7 2.4
6 146.0 2.0 105.0 1.9 1.9
18 198.0 15.8 422.0 3.7 7.0
20 236.0 8.8 288.4 3.0 3.5
12 289.0 3.6 80.5 4.5 8.0
16 304.0 38.8 1440.8 2.7 3.7
25 311.0 83.9 3651.0 2.3 3.2
ND, not detected.982 E Leygue et al
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determined by RNAase protection assay (in the 18 tumours in
which a C4 signal was detectable) and C4 mRNA relative expres-
sion determined by TP-PCR (r = 0.932, P < 0.0001). Interestingly,
an additional band was also observed in most of the samples using
the TP-PCR assay (see asterisk, Figure 1D). This band was identi-
fied after subcloning and sequencing to be a product of an exon 2-
duplicated ER variant mRNA. The intensity of the signal obtained
from this exon 2-duplicated ER band paralleled that of the WT ER
band, and the co-amplification of the exon 2-duplicated ER variant
mRNA using TP-PCR did not interfere with the relationship
between TP-PCR and RNAase protection assay.
Determination of the relative expression of clone 4
truncated ER variant mRNA expression
The above TP-PCR assay was used to compare the relative expres-
sion of C4 and WT ER expression in the matched breast cancer
samples (Figure 1D). The median relative expression of the C4 ER
for the primary tumours was 3.5% (range 1.6–10.5%) and the
median value for the matched lymph node metastases was 3.1%
(range 1.0–19.4%). A scatterplot of the results is shown in Figure
2C. There is no statistically significant difference in the relative
expression of C4 ER variant expression between primary breast
tumours and their concurrent lymph node metastases by Wilcoxon
rank-sum analysis. Interestingly, although not statistically signifi-
cant, we found that the median level of C4 expression in ER+ PR–
primary tumours, 3.7% (range 2.5–7.9%, n = 5), was approxi-
mately 50% higher than the median level of C4 expression in ER+
PR+ primary tumours, which was 2.4% (range 1.6–10.5%, n = 8).
Such a trend would be consistent with our previous results in
which C4 expression was higher in PR– primary breast tumours
than in PR+ primary tumours.
DISCUSSION
The data presented in this study provide evidence that both the
overall pattern of ER variant expression and the relative level of
expression of three individual ER variants are conserved in
primary breast tumours and their matched, concurrent lymph node
metastases.
The observations presented in this manuscript, showing a
conserved pattern and similar relative expression of ER variants
between primary tumours and their concurrent lymph node metas-
tases, would be consistent with previous observations that little
change of ER status can be found between primary human breast
tumours and their concurrent lymph node metastases or their distant
metastases (Hahnel and Twaddle, 1985; Robertson, 1996). These
findings are not inconsistent with our previously published data,
which showed that the relative expression of one ER variant was
significantly increased in primary tumours with poor prognostic
characteristics, which included having concurrent lymph node
metastases, as compared with primary tumours without concurrent
lymph node metastases (Murphy et al, 1995). It should be stressed
that all the primary tumours in the current study had concurrent
lymph node metastases, a major feature of poor prognosis in breast
cancer, and most likely resembled our previously described poor
prognostic group (Murphy et al, 1995). Therefore in primary
tumours that have concurrent lymph node metastases and have
detectable levels of C4 ER variant as well as other variant ER
mRNAs, mRNA levels do not significantly change between
primary tumours and their concurrent lymph node metastases.
These data do not, however, shed any light on whether tumours
with good prognostic features, as previously described (Murphy et
al, 1995), that have a relatively low level of C4 ER variant mRNA
subsequently develop higher levels when recurrent disease
develops. Although this issue remains to be investigated, our earlier
observation of higher relative C4 ER mRNA expression in PR–
primary tumours compared with PR+ primary tumours appeared to
be conserved in the present cohort, although the numbers were low
and the difference did not reach statistical significance. As quantita-
tive differences in the expression of several ER variants have been
shown to occur in primary breast tumours compared with normal
human breast tissues (Leygue et al, 1996a, b), as well as between
good vs poor prognosis primary breast tumours, the current data
suggest that alterations in ER variant expression and any role this
may have in altered oestrogen signal transduction probably occurs
early in tumorigenesis and well before the acquisition of the ability
to metastasize. This is consistent with previous data supporting the
concept of an early involvement of perturbations of oestrogen
signal transduction and the development of hormone independence
in breast tumorigenesis (Khan et al, 1994; Schmitt, 1995). It
remains therefore to be determined if altered ER variant expression
can predict tumour recurrence and progression in node-negative
breast cancers.
To our knowledge, this study is the first to compare an already
established quantitative approach, such as the RNAase protection
assay, with an RT-PCR based approach in the study of ER variant
mRNA expression. Earlier studies have utilized either the RNAase
protection assay or RT-PCR only. Considering the potential clinical
relevance of the measurement of the relative level of ER variants
with respect to WT ER within human breast tissue samples and the
sensitivity of an RT-PCR based approach, such a comparative study
was deemed necessary. Furthermore, our data provide validation
for comparing previous data obtained using a non-amplification-
dependent RNAase protection assay with the current data obtained
using an amplification-dependent TP-PCR assay.
The lack of sensitivity of the RNAase protection assay for a
subset of tumours with very low (<10 fmol mg–1) ER values by
ligand-binding assay is an important limiting factor. It effectively
means that, in a screening study, ER-negative tumours
(< 3 fmol mg–1 protein), as well as ER-positive tumours with ER
values lower than 10 fmol mg–1, as measured by ligand-binding
assay, cannot be reliably assessed for C4 ER variant mRNA
expression by RNAase protection assay. This, together with the
relatively large amount of RNA needed to perform an RNAase
protection analysis, severely limits the usefulness of a standard-
ized RNAase protection assay in such screening studies. The low
amount of starting material needed, together with the higher sensi-
tivity observed (samples C4 ER variant negative by RNAase
protection assay had detectable levels of C4 ER variant and WT
ER mRNA by TP-PCR) make TP-PCR an attractive alternative to
the RNAase protection assay in studies in which such factors are
limiting.
In conclusion, the current investigation extends our previous
studies on the relationship of ER variant expression and progres-
sion in human breast cancer. The data presented show that both the
pattern and level of expression of ER variants are conserved
between matched primary breast tumours and their concurrent
lymph node metastases. Therefore, any alteration in ER variant
expression that could be a marker of altered ER signal transduction
and breast cancer progression probably occurs before breast cancer
cells acquire the ability to metastasize.Oestrogen receptor-a variants in metastases 983
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